Lawmakers urge Trump administration action on DIR fees
Legislators have joined a group of pharmacy organizations in their advocacy efforts to fix pharmacy direct and indirect remuneration, or DIR fees. Nearly a quarter of the House of Representatives — 105 members — sent a letter to President Donald Trump noting the “missed opportunity” to reduce seniors’ out-of-pocket costs for prescription drugs. This missed opportunity occurred when pharmacy DIR fee reform was excluded from a recent Medicare rule.
The legislators, including one-third of the House Energy and Commerce Committee’s majority members, urged the administration to finalize pharmacy DIR reform this year. The bipartisan letter was led by community pharmacy champions Reps. Peter Welch, D-Vt., Vicente Gonzalez, D-Texas, Buddy Carter, R-Ga., and Morgan Griffith, R-Va.
Last week, 28 bipartisan members of the Senate, led by Sens. Shelley Moore Capito, R-W.Va. and Jon Tester, D-Mont., sent a similar letter.
The letter from House members cited Centers for Medicare & Medicaid Services data indicating that “DIR fees on pharmacies participating in Part D grew by 45,000% between 2010 and 2017.” The House members said, “This increase is unacceptable and unsustainable, and creates uncertainty not only for community and specialty pharmacies, but also for the patients who rely on Part D for prescription drugs. Until pharmacy DIR fee reform occurs, seniors will continue to pay higher cost-sharing for their prescription drugs.”
This extremely strong Congressional engagement was welcomed by the united voices of diverse pharmacy organizations. Issuing a joint statement were: National Community Pharmacists Association; National Association of Chain Drug Stores; National Association of Specialty Pharmacy; American Pharmacists Association; Food Marketing Institute; National Grocers Association; National Alliance of State Pharmacy Associations; and American Society of Consultant Pharmacists.
The pharmacy organizations said: “We appreciate this strong and bipartisan demonstration that DIR fee relief is needed now, to deliver savings to patients and to the Medicare program, and for the viability of pharmacies. It is essential that this powerful statement is translated into action on DIR relief this year, through Executive Branch action, through inclusion in drug-pricing legislation, or both. Reform is needed to address the gaming of the system through DIR fees, and to work toward pharmacy-specific metrics to enhance patient outcomes and appropriately evaluate pharmacy performance.”